Issue Date: May 21, 2012
Bosutinib Buyer Beware
Some bad bosutinib is going around. Scientists who have purchased the compound may actually have received an isomer rather than the genuine molecule.
Bosutinib, also known as SKI-606, is currently in Phase III clinical trials to treat chronic myeloid leukemia. Officials at Pfizer, the company sponsoring the clinical trials, say that only genuine bosutinib has been administered to patients. However, as a selective kinase inhibitor, the compound is also used in medical and . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society